Molnunat is an antiviral medication originally developed to treat influenza. It is currently being investigated for use against other rna viruses such as sars-cov-2. The drug works by interfering with the viral replication cycle. Its active ingredient inhibits the enzyme polymerase, which the virus relies on to copy its genetic material. By blocking this enzyme the medication reduces the spread of the virus inside infected cells. This inhibition leads to a decrease in viral load and helps the immune system clear the infection more effectively. The resulting drop in viral activity also lessens inflammation and related symptoms in patients.

Molnunat is an investigational antiviral medication being studied for its activity against certain viral infections. It belongs to a class of compounds that target viral replication enzymes in host cells. The drug acts by inhibiting a specific viral protease that is essential for the processing of viral polyproteins. This inhibition prevents the formation of mature infectious viral particles. By reducing the production of viable virus the medication supports the immune system in clearing infected cells. The mechanism involves binding to the active site of the protease and stabilizing an inactive conformation. The attachment leads to a cascade that ultimately stops viral growth and limits disease progression.

Molnunat may cause mild nausea in some patients. Headache is another reported symptom. Fatigue and dizziness have been observed during treatment. Some individuals experience mild skin rash or itching. Changes in liver enzyme levels have been noted in clinical studies. Gastrointestinal disturbances such as diarrhea can occur. Insomnia or difficulty sleeping has been documented in a small subset of cases. These reactions are generally transient and resolve after discontinuation.

Molnunat may cause mild headache in some patients. It can also lead to occasional nausea and vomiting. Some individuals experience fatigue that lasts a few days. A small number report dizziness or lightheadedness. Skin reactions such as rash or itching are possible. Laboratory tests sometimes show mild elevations in liver enzymes. Most side effects are transient and resolve without intervention.